Skip to content

One Health travel study - part II

One Health travel study - part II - OH travel part II

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON52107
Enrollment
70
Registered
2021-12-30
Start date
2022-09-24
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

seroconversion arboviruses Viruses transmitted by mosquitoes

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: Participating in the OH travel part I (OH travel part I is a non-wmo study 21-320) Providing a dried blood spot (DBS) that tested positive by serology. Positive samples are defined as samples that show reactivity against arbovirus NS1 or E proteins using a protein microarray.

Exclusion criteria

Exclusion criteria: Not willing to participate on part II

Design outcomes

Primary

MeasureTime frame
Neutralising antibody titers against each of the targeted arboviruses at two different time- points since exposure and fold difference in antibody titers between time point 1 and 2.

Secondary

MeasureTime frame
From confirmed seropositive participants longitudinal B-cell profiles and functional antibody data will be generated. These data included enumerating the number of reactive clones, their cross-reactivity potential towards heterologous arboviruses and phenotypic and functional characterization of arbovirus-reactive clones. For these assays recombinant antibodies will be generated. These clones will be shared with the scientific community via the European virus archive - global, for assay standardization and quality control. Determinants of functional antibody response, such as age, gender and time since exposure might be also explored.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)